[Changes of the complement system in myelodysplastic syndromes]

Area of Science:

• Immunology
• Hematology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• MDS are characterized by ineffective hematopoiesis and a significant risk of progression to acute myeloid leukemia.
• Complement system dysregulation may play a role in MDS pathogenesis.

Purpose of the Study:

• To investigate complement system activity in patients with myelodysplastic syndromes (MDS).
• To detect circulating immune complexes in MDS patients.
• To compare complement activity between MDS subgroups with favorable and unfavorable prognoses.

Main Methods:

• Studied 28 MDS patients, categorized into favorable (refractory anemia, refractory ringed sideroblastic anemia) and unfavorable (refractory anemia with blastic excess, refractory anemia with blastic excess in transformation) prognosis subgroups.
• Assessed complement system components: factor B, classical and alternative hemolytic activity, C3, and C4 levels.
• Detected circulating immune complexes using C1q deviation and polyethylene glycol precipitation methods.

Main Results:

• Patients with unfavorable prognosis MDS exhibited significantly lower C3 levels compared to favorable prognosis groups and healthy controls.
• A notable decrease in alternative hemolytic activity and factor B was observed in the unfavorable prognosis MDS subgroups.
• No specific mention of circulating immune complexes detection results in the abstract.

Conclusions:

• The findings suggest a potential role for complement system alterations in the pathophysiology of unfavorable prognosis MDS.
• Reduced complement activity may indicate an increased susceptibility to or presence of subclinical infections in these patients.